Covestor LTD Biomarin Pharmaceutical Inc Transaction History

Covestor LTD

$160 Million
Q3 2024

A detailed history of Covestor LTD transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Covestor LTD holds 1,030 shares of BMRN stock, worth $68,628. This represents 0.05% of its overall portfolio holdings.

Number of Shares

1,030

Previous 236 336.44%

Holding current value

$68,628

Previous $19,000 278.95%

% of portfolio

0.05%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	BUY	$69.02 - $93.84 $54,801 - $74,508	794 Added 336.44%	1,030 $72,000
Q2 2024 Aug 09, 2024	SELL	$74.43 - $92.22 $29,250 - $36,242	-393 Reduced 62.48%	236 $19,000
Q1 2024 May 10, 2024	SELL	$83.81 - $99.0 $2,849 - $3,366	-34 Reduced 5.13%	629 $55,000
Q4 2023 Feb 09, 2024	SELL	$76.22 - $98.51 $7,926 - $10,245	-104 Reduced 13.56%	663 $64,000
Q3 2023 Nov 13, 2023	BUY	$85.07 - $94.48 $8,081 - $8,975	95 Added 14.14%	767 $68,000
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $86 - $100	-1 Reduced 0.15%	672 $58,000
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $29,480 - $39,402	336 Added 99.7%	673 $66,000
Q4 2022 Feb 13, 2023	BUY	$80.93 - $108.63 $13,677 - $18,358	169 Added 100.6%	337 $34,000
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $82 - $96	-1 Reduced 0.59%	168 $14,000
Q2 2022 Aug 10, 2022	SELL	$71.48 - $86.85 $285 - $347	-4 Reduced 2.31%	169 $14,000
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $5,422 - $6,766	73 Added 73.0%	173 $13,000
Q4 2021 Feb 10, 2022	BUY	$71.72 - $91.47 $7,172 - $9,147	100 New	100 $9,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Covestor LTD, based on Form 13F filings with the SEC.

News

Stay updated on Covestor LTD with notifications on news.

Account